NCT01314391

Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor

Pilot Case-Control Study of WT1 Mutations in Wilms Tumor Patients Who Develop ESRD

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 20 (estimated)
• Sponsor: Children's Oncology Group · Network
• Sex: All
• Age: 15 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in blood and tumor tissue samples from patients with Wilms tumor.

Detailed description

OBJECTIVES: * To determine whether Wilms Tumor (WT) patients without WT1-associated congenital anomalies or syndromes, but with end-stage renal disease (ESRD) unrelated to progressive bilateral tumors, carry germline WT1 mutations. * To determine whether non-syndromic WT1 germline mutation carriers have a substantially higher incidence of ESRD than do WT patients who do not harbor WT1 mutations. OUTLINE: Archived blood and tumor tissue specimens (or DNA isolated from these samples) are analyzed for WT1 mutations by gene sequencing and PCR.

Conditions

• Kidney Cancer
• Renal Failure

Interventions

Type	Name	Description
GENETIC	mutation analysis
GENETIC	polymerase chain reaction
OTHER	laboratory biomarker analysis

Timeline

• Start date: 2011-08-01
• Primary completion: 2016-05-01
• First posted: 2011-03-14
• Last updated: 2016-05-18